key: cord-0907085-1mws6u5h
authors: Hernández-Doño, Susana; Sánchez-González, Roberto Alejandro; Trujillo-Vizuet, Ma Guadalupe; Zamudio-Castellanos, Fabiola Yeseline; García-Silva, Rafael; Bulos-Rodríguez, Pedro; Vazquez-Guzmán, Carlos A.; Cárdenas-Ramos, Ximena; de León Rodríguez, Diana; Elías, Fabiola; Domínguez-Arevillaga, Sergio; Pérez-Tirado, José Manuel; Vera-Lastra, Olga Lidia; Granados, Julio; Sepúlveda-Delgado, Jesús
title: Protective HLA alleles against severe COVID-19: HLA-A*68 as an ancestral protection allele in Tapachula-Chiapas, Mexico
date: 2022-04-05
journal: Clin Immunol
DOI: 10.1016/j.clim.2022.108990
sha: 520316c992aa694b7f9195ed1dcac723335f14bf
doc_id: 907085
cord_uid: 1mws6u5h

HLA is a polymorphic antigen presenter which has provided valuable information on the susceptibility of populations to viruses. Therefore, the study of HLA can reveal specific susceptibility or resistance alleles to severe COVID-19 in an ethnically dependent manner. This pilot study investigated HLA alleles associated with COVID-19 severity in Tapachula, Chiapas, Mexico. A total of 146 Mexican Mestizos were typed for HLA class I and II using PCR-SSP. The patients were classified according to the outcome (death or improvement) and the infection's severity (mild or severe). In addition, a group of exposed uninfected individuals was included. HLA-A*68 was found to be a protective allele against the severe infection and fatal outcome; pC = 0.03, OR = 0.4, 95% CI =0.20–0.86, and pC =0.009, OR = 0.3, 95% CI =0.13–0.71 respectively. HLA-DRB1*03 also appears to be a protective factor against fatal outcome pC = 0.009, OR = 0.1, 95%IC = 0.01–0.66; however, the low frequency of this allele in the studied population limits the statistical power. The severity and fatal outcome of COVID-19 patients in Tapachula, Chiapas depend more on the lack of resistance than susceptibility HLA alleles.

Coronavirus disease 2019 , caused by severe acute syndrome coronavirus 2 (SARS-CoV-2), has been the most challenging outbreak in recent history globally. It has had more impact than the outbreak produced by the severe acute respiratory syndrome (SARS-CoV) and Middle East Respiratory Syndrome (MERS-CoV) (1) . COVID-19 has a lethality rate, severity, and clinical behavior varying due to various factors that continue to be studied, such as age, comorbidities, geographical situation, and genetic predisposition.

GWAS studies have insight into genetic variants linked to susceptibility and severity in COVID-19, most of them implicated in immunological processes (2) . The immune response's effectiveness lies in the antigen presentation through Human Leukocyte Antigen (HLA), which varies among individuals.

The COVID- 19 Tapachula study was conducted in the "Clínica de enfermedades Respiratorias COVID- 19 ", a care facility that provided attention to COVID-19 non-insured patients (unemployed population).

We enrolled any subject needing care attention for respiratory symptoms in the last seven days, independently of their requirement of hospitalization, that fulfilled the following eligibility criteria: 1) Met the operational definition of a suspected case of COVID-19 disease following WHO/PAHO, for the presence of sudden onset of fever and cough or sudden onset of three or more of the following symptoms: fever, cough, weakness or fatigue, headache, myalgia, sore throat, nasal cold, dyspnea, anorexia, nausea, vomiting, diarrhea or altered mental state; 2) has an available nasopharyngeal and/or pharyngeal swab for confirmation of SARS-CoV-2 infection; and 3) agreement of participation through an informed consent form. We excluded subjects with more than seven days of onset of symptoms at the moment of pharyngeal or nasopharyngeal swab collection. We prospectively collected all enrolled subjects' clinical and biochemical data through case report form (CRF).

The diagnosis of SARS-CoV-2 infection of the patients enrolled was made in pharyngeal and nasopharyngeal swabs collected at seven days since the onset of symptoms. We used CDC 2019-Novel Coronavirus (2019-nCoV) and proceeds as manufacturer indications (13).

To classify the severity of the disease, we used as a reference the ordinal scale of clinical improvement of the World Health Organization (WHO), which classifies the severity of COVID-19 in eight J o u r n a l P r e -p r o o f categories, evaluating the need for oxygen and advanced support. The categories are as follows: 1) nonhospitalized without limitations of activities. 2) Non-hospitalized: activity limitation, home oxygen requirement, or both. 3) Hospitalized does not require supplemental oxygen and no longer requires ongoing medical attention (if hospitalization was extended for infection control reasons). 4) Hospitalized, not requiring supplemental oxygen but requiring continuous medical care (covid-19 related or other medical conditions). 5) Hospitalized, requiring supplemental oxygen. 6) Hospitalized, requiring non-invasive ventilation or the use of high flow oxygen devices. 7) Hospitalized, receiving invasive mechanical ventilation extracorporeal membrane oxygenation (ECMO), and 8) death. We calculated the score based on CRF records collected in each study visit.

The classification of individuals was performed with the guidance of the WHO system. Patients with classifications 1, 2, and 3 were regrouped as mild, while individuals with ratings from 5 to 8 were regrouped as severe. 1-3 were integrated as mild since they did not require mechanical ventilation or strict medical surveillance, while strata 5-8 required hospitalization or oxygen or mechanical respiratory assistance and/or strict medical surveillance. This simplification of the WHO classification was based on the medical experience at that time since the patients who required respiratory assistance or strict medical surveillance because of SARS-CoV-2 infection or other concomitant conditions progressed to the severe estate in most cases and many with fatal outcomes.

For this study, the groups to compare Class I and II HLA's allelic frequencies were classified by the primary outcome (deceased and recovered) of the COVID-19. The severity of the symptoms at the first 24 hours after enrollment (mild and severe) was the other classification criterion. An additional group J o u r n a l P r e -p r o o f without infection was included as a reference group. This reference group included exposed individuals with negative qRT-PCR for SARS-CoV-2 infection.

The COVID-19 Tapachula Study fulfilled the principles of the Helsinki Declaration. The study protocol was evaluated and approved by the ethics and research committee of the Hospital Regional de Alta Especialidad Ciudad Salud (Id: 08/2020) and the research and ethics committee of the Ministry of Health of the state of Chiapas (Id: EADIS -010-2020). Participation was voluntary, and specific procedures were presented in writing in informed consent. All participants were over 18 years of age and gave their permission. If individuals had not been in eligible conditions, legal representatives authorized their participation. The data collected from each patient was captured in electronic databases and managed as confidential. Any informed consent form was obtained for the retrospective study, guaranteeing confidentiality and anonymization of data.

Genomic DNA was obtained from peripheral blood collected in EDTA tubes using the QIAamp DNA mini kit (Qiagen, Valencia, CA, USA). The DNA quality was assessed through spectrophotometry technique and agarose electrophoresis. HLA class I and II typing was performed using PCR-SSP FluoGene V 1.5.5.x (Inno-Train Diagnosetik GmbH, Kronberg im Taunus, Germany) software. This software assigns the appropriate results.

Differences in HLA class I and II frequencies were analyzed using X 2 , and p-values less than 0.05 were considered statistically significant. If appropriate, the p-values were also corrected using the Bonferroni method (for allele frequencies, multiplying the original p-value by the number of alleles); odds ratios and 95% confidence intervals (95%CI) were calculated to measure association strength with EPIINFO v7 software. Descriptive statistics were performed using the SPSS program.

111 cases representing the whole spectrum of disease severity and the primary outcome were included.

Those cases were considered in the present report. There were 51 mild and 60 severe cases; of the 111 patients studied, 69 patients recovered from COVID-19, while 42 died during follow-up. The exposed non-infected group consisted of 22 males (63%) and 13 females (37%) with a mean age of 46.3 ± 6.4 years.

The patients' main clinical and sociodemographic characteristics are shown for each group in Table 1 .

Most of the symptoms showed an average distribution among the group; only dyspnoea showed statistical difference being evaluated by the outcome and the severity level at the first 24 hours of hospital admission. The dyspnoea had a negative impact on the outcome. Deceased patients showed a higher frequency of dyspnoea than recovered patients, pC=0.00004, OR=8.07, 95%IC=2.83-22.98.

Similarly, the dyspnoea frequency was higher in severe than mild patients pC=6.5E-7, OR=8.9, 95%IC=3.71-21.38. There was no statistical association among symptoms and specific HLA Class I or II alleles.

The Hardy Weinberg equilibrium (HWE) was calculated for the included Class I and II loci (Supplementary material S2). The estimation was performed using ARLEQUIN 3.5.2.2 human genetics program.

HLA-A*68. The comparison between COVID-19 patients and exposed non-infected individuals showed statistically significant differences, showing the HLA-A*68 as resistance factor pC=0.003, OR=0.4, 95%IC=0.19-0.69 ( Table 2 ). The comparison between severe COVID-19 patients and exposed noninfected individuals showed statistically significant differences pC=0.03, OR=0.4, 95% IC=0.20-0.86 (Table 3) . This data means the frequency of HLA-A*68 is diminished in Severe COVID-19 patients, and it confers 2.4 times the resistance against SARS-CoV-2 severe infection to carriers. In the same way, the comparison between diseased COVID-19 patients and exposed non-infected individuals showed statistically significant differences pC=0.009, OR=0.3, 95% IC=0.13-0.71 (Table 4 ). This data means the frequency of HLA-A*68 is diminished in diseased COVID-19 patients, and it confers 3. HLA-DQB1*02. The analysis between severe COVID-19 patients and exposed non-infected individuals showed statistically significant differences pC=0.05, OR=0.2, 95% IC=0.04-0.89 (Table 3 ). This data means the frequency of HLA-DQB1*02 is diminished in Severe COVID-19 patients, and it confers 5.5

times the resistance against SARS-CoV-2 severe infection to carriers. Likewise, the comparison between the deceased group and the exposed non-infected showed a diminished frequency of HLA-DQB1*02 HLA-DRB1*03. The comparison between COVID-19 patients and exposed non-infected individuals showed statistically significant differences pC=0.0003, OR=0.1, 95% IC=0.04-0.42 (Table 2 ). It shows 8.04 times protection for carriers. While the comparison between severe COVID-19 patients and exposed non-infected individuals showed statistically significant differences pC=0.01, OR=0.2, 95%

IC=0.05-0.67 (Table 3) . It confers 5.7 times protection against developing the severe disease for carriers.

Similarly, when compared deceased COVID-19 patients and exposed non-infected individuals was obtained pC=0.009, OR=0.1, 95% IC=0.01-0.66. (Table 4 ). This represents a decrease in allele 

In this pilot study in Tapachula 

Recently, the extended haplotypes HLA-A*02:05~B*58:01~C*07:01~DRB1*03:01 and HLA-A*01:01~B*08:01~C*07:01~DRB1*03:01 have been cataloged with a protective effect against SARS-CoV-2 infection in an ethnically dependent manner (27, 28) . However, we emphasize that the low frequency of HLA-DRB1*03 has limited a categoric conclusion of the resistance role of HLA-DRB1*03

in the Tapachula, Chiapas populace. On the other hand, the HLA-DRB1*08, an autochthonous and highfrequency allele in this populace, is a risk factor in two studies. Peptide binding prediction analyses showed that these HLA-DRB1*08 alleles could not bind any viral peptides with high affinity (27, 29) .

However, this fact has not been evident in this study. presentation (38) . Notably, HLA-DQ2 has reduced DM interaction compared with most other alleles J o u r n a l P r e -p r o o f (38) (39) (40) . In this context, the apparent protective role of HLA-DRB1*02 could be related to a less dynamic process of viral peptide presentation and the retarding or abolishment of the onset of the immune and inflammatory response. Which, on the contrary, is disadvantageous in inducing immunity with certain vaccines.

In contrast, it was observed an increased frequency of the haplotype DRB1*15~DQA1*01~DQB1*06 as the severity, and the worsening of COVID-19 increased. The HLA-DRB1*15:01 and -DQB1*06:02

have been found as risk alleles for COVID-19 in Italian patients (41) . Furthermore, this haplotype and the individual alleles have been associated with autoimmunity and cancer in specific seropositive individuals. For instance, the HLA-DR15-DQ6 and tumor necrosis factor a-11 haplotype increase the risk for cervical intraepithelial neoplasia in human papillomavirus 16 seropositive women (42) .

Additionally, it has been determined that HLA-DRB1*15 restricts an epitope on dengue-4 recognized by human CD4+ CD8-cytotoxic T lymphocyte clones, showing a flavivirus-cross-reactive reaction (43) .

Other studies have associated HLA-DRB1*15 with no Virus C hepatitis progression in an ethnically dependent manner (44) . In silico studies have predicted more than 628 epitopes in the S protein for HLA Class II, which underlines the importance of studying HLA in different populations, considering the admixture.

Further studies in the Mexican population are necessary to accomplish the differences in some of the wealthiest admixed populations and know the influence of the genetic background in responding to the disease that has been markedly differing around the country.

This study's slight association of some HLA-Class II alleles shows that the severity of COVID-19 is described partly as an autoimmune phenomenon. In contrast, disease onset and progression by viral infections are usually associated with Class I polymorphisms.

It is well known that genetic factors partially contribute to the clinical outcome. Nevertheless, other confusing factors might also be applied-comorbidities, such as hypertension, diabetes, male gender, and older age. Interestingly, none of them are statistically relevant in this study. The only clinical feature that reached statistical significance was the presence of dyspnoea in the more severe cases. This may be related to access to health care providers in specialized hospitals.

Finally, it was noteworthy that HLA-DR alleles were in Hardy Weinberg equilibrium in patients and controls except for the severe and deceased groups, which required further investigation. The slight deviation from HWE could tell us something about the dynamic of autoimmune response HLA-Class IImediated in Severe SARS-CoV-2 infected individuals who are driven to a fatal outcome. The HLA-DQB1*02 frequency for the COVID-19 group is based on a total of 204 alleles. The HLA-DQB1*02 frequency for the Severe COVID-19 group is based on a total of 102 alleles. 

Genetic variability in the case of COVID-19 infection

Genetic mechanisms of critical illness in COVID-19

An Increased Frequency in HLA Class I Alleles and Haplotypes Suggests Genetic Susceptibility to Influenza A (H1N1) 2009 Pandemic: A Case-Control Study

A comparative review of HLA associations with hepatitis B and C viral infections across global populations

Downregulation of MHC Class I Expression by Influenza A and B Viruses

Conserved extended haplotypes of the major histocompatibility complex: further characterization

Human leukocyte antigen susceptibility map for SARS-CoV-2

Ethnic and geographical differences in HLA associations with the outcome of hepatitis C virus infection

Human Leukocyte Antigen Susceptibility Map for Severe Acute Respiratory Syndrome Coronavirus 2

Suboptimal SARS-CoV-2-specific CD8(+) T cell response associated with the prominent HLA-A*02:01 phenotype

COVID-19 infection: the perspectives on immune responses. Cell Death Differ. 272020

SARS-COV-2 INFECTED PATIENTS. Rev Invest Clin. 72. Mexico2020. p. 178-9. 13. Prevention CfDCa. 2019-Novel Coronavirus (2019-nCoV) Real-time

Primers and Probes: CDC. Division of Viral Diseases

Distribution of HLA-B alleles in Mexican Amerindian populations

Genetic diversity of HLA system in two populations from Yucatán, Mexico: Mérida and rural Yucatán

HLA genetic profile of Mapuche (Araucanian) Amerindians from Chile

Extended HLA haplotypes in a Carib Amerindian population: the Yucpa of the Perija Range

Demographic history and selection at HLA loci in Native Americans

Genetic diversity of HLA system in two populations from Chiapas

Possible role of HLA class-I genotype in SARS-CoV-2 infection and progression: A pilot study in a cohort of Covid-19 Spanish patients

-2 surface proteins: In-silico hypothetical evidence for the immunopathogenesis of Guillain-Barré syndrome

Airway Memory CD4(+) T Cells Mediate Protective Immunity against Emerging Respiratory Coronaviruses

Long-lived memory T lymphocyte responses against SARS coronavirus nucleocapsid protein in SARS-recovered patients

Association of human-leukocyte-antigen class I (B*0703) and class II (DRB1*0301) genotypes with susceptibility and resistance to the development of severe acute respiratory syndrome

Human-leukocyte antigen class I Cw 1502 and class II DR 0301 genotypes are associated with resistance to severe acute respiratory syndrome (SARS) infection

Human Leukocyte Antigen Complex and Other Immunogenetic and Clinical Factors Influence Susceptibility or Protection to SARS-CoV-2 Infection and Severity of the Disease Course

Correlation of the two most frequent HLA haplotypes in the Italian population to the differential regional incidence of Covid-19

HLA and AB0 Polymorphisms May Influence SARS-CoV-2 Infection and COVID-19 Severity

HLA-DRB1, DQA1 and DQB1 alleles and haplotypes frequencies in Iranian healthy adult responders and non-responders to recombinant hepatitis B vaccine

Genetic prediction of nonresponse to hepatitis B vaccine

Humoral response to recombinant hepatitis B virus vaccine at birth: role of HLA and beyond

Hepatitis C recurrence after liver transplantation: has the human leukocyte antigen mismatching at individual loci a role?

Role of HLA allele polymorphism in chronic hepatitis B virus infection and HBV vaccine sensitivity in patients from eastern Turkey

Risk of celiac disease in children with type 1 diabetes is modified by positivity for HLA-DQB1*02-DQA1*05 and TNF -308A

Class II allele and haplotype frequencies in Mexican systemic lupus erythematosus patients: the relevance of considering homologous chromosomes in determining susceptibility

HLA-DM constrains epitope selection in the human CD4 T cell response to vaccinia virus by favoring the presentation of peptides with longer HLA-DMmediated half-lives

key regulators of MHC-II processing and presentation

An insertion mutant in DQA1*0501 restores susceptibility to HLA-DM: implications for disease associations

Type 1 diabetes associated HLA-DQ2 and DQ8 molecules are relatively resistant to HLA-DM mediated release of invariant chain-derived CLIP peptides

HLA allele frequencies and susceptibility to COVID-19 in a group of 99 Italian patients

Tumor necrosis factor a-11 and DR15-DQ6 (B*0602) haplotype increase the risk for cervical intraepithelial neoplasia in human papillomavirus 16 seropositive women in Northern Sweden

Flavivirus-cross-reactive, HLA-DR15-restricted epitope on NS3 recognized by human CD4+ CD8-cytotoxic T lymphocyte clones

Increased frequency of the HLA-DR15 (B1*15011) allele in German patients with self-limited hepatitis C virus infection

The authors thank all individuals with COVID-19 and healthy controls who have participated in this genetic study.